Logo image of TRML

TOURMALINE BIO INC (TRML) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TRML - US89157D1054 - Common Stock

47.98 USD
0 (0%)
Last: 10/27/2025, 8:00:02 PM
47.98 USD
0 (0%)
After Hours: 10/27/2025, 8:00:02 PM
Fundamental Rating

3

Overall TRML gets a fundamental rating of 3 out of 10. We evaluated TRML against 528 industry peers in the Biotechnology industry. While TRML has a great health rating, there are worries on its profitability. TRML does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TRML had negative earnings in the past year.
  • In the past year TRML has reported a negative cash flow from operations.
  • In the past 5 years TRML always reported negative net income.
  • In the past 5 years TRML always reported negative operating cash flow.
TRML Yearly Net Income VS EBIT VS OCF VS FCFTRML Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • TRML has a Return On Assets of -32.79%. This is in the better half of the industry: TRML outperforms 64.74% of its industry peers.
  • TRML has a Return On Equity of -34.07%. This is in the better half of the industry: TRML outperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -32.79%
ROE -34.07%
ROIC N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
TRML Yearly ROA, ROE, ROICTRML Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • TRML does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRML Yearly Profit, Operating, Gross MarginsTRML Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • TRML has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TRML has been increased compared to 5 years ago.
  • TRML has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRML Yearly Shares OutstandingTRML Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
TRML Yearly Total Debt VS Total AssetsTRML Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 72.27 indicates that TRML is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of TRML (72.27) is better than 98.51% of its industry peers.
  • TRML has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 72.27
ROIC/WACCN/A
WACCN/A
TRML Yearly LT Debt VS Equity VS FCFTRML Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 24.68 indicates that TRML has no problem at all paying its short term obligations.
  • TRML has a Current ratio of 24.68. This is amongst the best in the industry. TRML outperforms 96.64% of its industry peers.
  • TRML has a Quick Ratio of 24.68. This indicates that TRML is financially healthy and has no problem in meeting its short term obligations.
  • TRML has a better Quick ratio (24.68) than 96.64% of its industry peers.
Industry RankSector Rank
Current Ratio 24.68
Quick Ratio 24.68
TRML Yearly Current Assets VS Current LiabilitesTRML Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.79% over the past year.
EPS 1Y (TTM)6.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, TRML will show a decrease in Earnings Per Share. The EPS will decrease by -7.61% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-33.34%
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%
EPS Next 5Y-7.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRML Yearly Revenue VS EstimatesTRML Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
TRML Yearly EPS VS EstimatesTRML Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TRML. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRML. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRML Price Earnings VS Forward Price EarningsTRML Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRML Per share dataTRML EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as TRML's earnings are expected to decrease with -17.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for TRML!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TOURMALINE BIO INC

NASDAQ:TRML (10/27/2025, 8:00:02 PM)

After market: 47.98 0 (0%)

47.98

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners89.14%
Inst Owner Change-0.1%
Ins Owners10.48%
Ins Owner Change-2685.68%
Market Cap1.24B
Revenue(TTM)N/A
Net Income(TTM)-88.30M
Analysts70.67
Price Target48.96 (2.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)4.36%
Max EPS beat(2)6.49%
EPS beat(4)4
Avg EPS beat(4)5.03%
Min EPS beat(4)2.86%
Max EPS beat(4)6.49%
EPS beat(8)6
Avg EPS beat(8)-3.2%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.13%
PT rev (3m)-13.82%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)-6.12%
EPS NY rev (3m)-5.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.77
P/tB 4.77
EV/EBITDA N/A
EPS(TTM)-3.43
EYN/A
EPS(NY)-4.17
Fwd EYN/A
FCF(TTM)-3.35
FCFYN/A
OCF(TTM)-3.35
OCFYN/A
SpS0
BVpS10.06
TBVpS10.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.79%
ROE -34.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.68
Quick Ratio 24.68
Altman-Z 72.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)137.69%
Cap/Depr(5y)218.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
EPS Next Y-33.34%
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%
EPS Next 5Y-7.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-84.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.41%
OCF growth 3YN/A
OCF growth 5YN/A

TOURMALINE BIO INC / TRML FAQ

Can you provide the ChartMill fundamental rating for TOURMALINE BIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRML.


What is the valuation status for TRML stock?

ChartMill assigns a valuation rating of 0 / 10 to TOURMALINE BIO INC (TRML). This can be considered as Overvalued.


Can you provide the profitability details for TOURMALINE BIO INC?

TOURMALINE BIO INC (TRML) has a profitability rating of 1 / 10.


What is the earnings growth outlook for TOURMALINE BIO INC?

The Earnings per Share (EPS) of TOURMALINE BIO INC (TRML) is expected to decline by -33.34% in the next year.